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Abstract Human papilloma virus (HPV) is recognized as a major cause for cervical cancer among 
women worldwide. Two 
HPV vaccines are currently available: Gardasil" and Cervarix". Both vaccines enclose viral 
antigenic proteins, but differ as to 
the biological systems of culture and the adjuvant components. Recently, a collection of 
symptoms, indicating nervous system 
dysfunction, has been described after HPV vaccination. We retrospectively described a case 
series including 18 girls (aged 
12–24 years) referred to our ‘‘Second Opinion Medical Network’’ for the evaluation of 
‘‘neuropathy with autonomic dysfunction’’ 
after HPV vaccination. All girls complained of long-lasting and invalidating somatoform 
symptoms (including 
asthenia, headache, cognitive dysfunctions, myalgia, sinus tachycardia and skin rashes) that have 
developed 1–5 days 
(n = 11), 5–15 days (n = 5) and 15–20 days (n = 2) after the vaccination. These cases can be 
included in the recently 
described immune dysfunction named autoimmune/inflammatory syndrome induced by 
adjuvants (ASIA). HPV vaccine, 
through its adjuvant component, is speculated to induce an abnormal activation of the immune 
system, involving glia cells in 
the nervous system too. Further researches should aim at defining the pathological and clinical 
aspects of these postvaccination 
diseases and identifying a genetic background predisposing to these adverse reactions. 
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Introduction 
Human papilloma virus (HPV) infection has been recognized 
to have a significant role in the occurrence and 
progression of several tumours, such as cervical cancer, 
representing one of the most common malignancies among 
women worldwide [1]. 
Following this discovery, some vaccines have been 
produced to prevent such a sexually transmitted infection, 
against the most frequently involved serotypes, namely 
HPV-6, HPV-11, HPV-16 and HPV-18. Particularly, the 
latter two have been estimated to account for 70 % of cases 
of cervical cancer [2]. 
Currently, two HPV vaccines are available on the market: 
Gardasil" (a quadrivalent vaccine covering serotypes 
6, 11, 16 and 18) was licensed in 2006 and Cervarix" (a 
bivalent vaccine against HPV-16 and HPV-18) in 2009. 
Both vaccines enclose self-assembled antigenic pentamers 
of L1 proteins, produced by DNA recombinant technology, 
but differ as to the biological system of culture and the 
adjuvant components, as summarized in Table 1. Gardasil" 
is produced by Saccharomyces cerevisiae cells, and viral 
antigens are pooled with the adjuvant aluminium hydroxyphosphate 
sulphate (225 lg). Cervarix" is obtained 
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through a L1-recombinant baculovirus-infected insect 
(Spodoptera frugiperda Sf9, Trichoplusia ni Hi-5), and the 
adjuvant component is represented by ASO4 complex that 
is made of aluminium hydroxide and Salmonella minnesota 
lipopolysaccharide extract. The intramuscular (IM) 
administration protocol encompasses three bimonthly 
injections that elicit a strong persisting antibody titre 
against HPV serotypes over six months and a good control 
of its related infection [3–5]. 
So far, more than 100 million HPV vaccine doses have 
been administered worldwide and it has been shown to 
provide protective and long-lasting antibody titres against 
the virus. The largest study investigating the safety of HPV 
vaccine included almost 300,000 young girls administered 
with nearly 700,000 doses of the quadrivalent vaccine: no 
increases in the number of cases of autoimmune and/or 
neurological diseases were detected. Moreover, a pooled 
analysis of five clinical trials involving 11,778 quadrivalent 
HPV vaccinated people and 9686 placebo-treated controls, 
aged 9–26 years, showed that 0.2 % of both vaccine and 
placebo recipients had dropped out because of adverse drug 
reactions (ADRs). Most dropouts occurred after the first 
dose and the most severe cases were due to autoimmunity; 
however, those events affected equally the vaccine 
and placebo groups [6–18]. 
The temporal relationship between the vaccination and the 
development of immune-mediated diseases raised the issue of 
the possible aetiological or co-causative role of such an immunization 
procedure, which may occur in patients with a 
genetic predisposition. Moreover, long-standing neurological 
and/or psychiatric symptoms after HPV vaccine being 
refractory to any treatment elicited further concerns [19–21]. 
Recently, these ADRs have been pooled in a heterogeneous 
group of medical conditions (including also Gulf 
War syndrome, macrophagic myofasciitis, siliconosis, sick 
building syndrome) named autoimmune/inflammatory 
syndrome induced by adjuvants (ASIA). The common 
feature of different ASIA clinical conditions is considered 
to be the previous exposure to an external stimulus (including 
vaccines) triggering an undefined immune-mediated 
response elicited by its adjuvant properties [22–25]. 
Here an incidental finding of a small cluster of young 
females with severe and persistent neurological and/or 
psychiatric symptoms arising after HPV vaccination led us 
to review critically this issue. 
Case series 
In 2015, through our ‘‘Second Opinion Medical Network’’, 
we have been asked for evaluating a girl with cervical 
lymphadenitis, headache, severe persistent fibromyalgialike 
pain, paresthaesia, chronic fatigue, insomnia, cognitive 
impairment, abnormal menstrual cycles and fingers/toes 
vascular abnormalities (changes in skin colour and temperature 
perception). Such a clinical picture was defined 
(by the neurologists evaluating the patient) as ‘‘neuropathy 
with autonomic dysfunction’’. Later, some other families 
Table 1 Characteristics of human papillomavirus (HPV) vaccines 
Type of HPV 
vaccine 
Gardasil" Cervarix" 
Protection against 
HPV genotypes 
(amount) 
Quadrivalent human papillomavirus (types 6, 11, 16, 18) 
recombinant vaccine 
Bivalent human papillomavirus (types 16, 18) 
recombinant vaccine 
Vaccine 
composition 
Each dose contains 20 lg of HPV 6 L1 protein, 40 lg of HPV 
11 L1 protein, 40 lg of HPV 16 L1 protein, and 20 lg of 
HPV 18 L1 protein 
Each dose contains 20 lg of HPV 16 L1 protein and 
20 lg of HPV 18 L1 protein 
Producer cells Saccharomyces cerevisiae Spodoptera frugiperda SF9, Trichoplusia ni Hi 5 
Adjuvants and 
inactive 
ingredients 
Each dose of the vaccine contains 225 lg of aluminium [as 
amorphous aluminium hydroxyphosphate sulphate (AAHS) 
adjuvant], 9.56 mg of sodium chloride, 0.78 mg of Lhistidine, 
50 lg of polysorbate 80, 35 lg of sodium borate 
and water for injection 
Each dose of the vaccine contains 500 lg of aluminium 
(hydroxide salt), 50 lg of 3-O-desacyl-40 
monophosphoryl lipid A, 4.4 mg of sodium chloride, 
0.624 mg of sodium dihydrogen phosphate dihydrate 
and water for injection 
Route of 
administration 
Intramuscular injection Intramuscular injection 
Dosage 9–26 years: 0.5 mL dose at 0, 2 and 6 months 9–14 years: two 0.5 mL doses each of 0.5 ml. The 
second dose given between 5 and 13 months after the 
first dose 
From 15 years and above: three 0.5 mL doses at 0, 1, 
6 months 
Manufacturing Merck Canada Inc. GlaxoSmithKline—GSK 
from Northern and Central Italy, whose daughters had been 
complaining of similar symptoms after HPV vaccination, 
were referred to our centre through the mother of this first 
patient. That fact allowed us to visit and analyse a case 
series including 18 young girls aged 12–24 years who 
developed post-vaccination phenomena after receiving 
Gardasil" (n = 9) or Cervarix" (n = 9). Patients’ and 
immunization features are reported in Table 2. An overview 
of the clinical manifestations considering the temporal 
association with HPV immunization is reported in 
Table 3. Current and persisting clinical problems are 
summarized in Table 4. 
Results 
Eighteen girls (aged 12–24 years, current mean age being 
15.2 years) have been included in this case series. As 
concerns their past personal history, all of them reported 
chickenpox during childhood, and some had mononucleosis 
(n = 4), scarlet fever (n = 2), fifth disease (n = 2) or 
CMV-related eruption (n = 1). During childhood, eight 
patients received the MMR (measles, mumps and rubella) 
vaccine, in addition to the regular immunization schedule 
administered at that time, including at least DTP, 
poliomyelitis and HBV. Nine girls were vaccinated against 
HPV via the quadrivalent vaccine (Gardasil"), between 
January 2008 and December 2015, and nine girls received 
HPV-16/18 vaccine (Cervarix") between January 2008 and 
December 2015 (Cervarix"). The mean age at HPV 
immunization was 11 and 12 years (Table 2). 
The ADRs described in Table 3 occurred after the first 
IM injection in four girls, after the second dose in eight 
patients and after the third boost in six of them. As 
expected, the first two groups refused the following doses 
of the HPV immunization protocol. Based upon the time 
interval between vaccination and symptoms onset, we 
divided our patients in three groups (Table 3): (1) girls 
whose symptoms appeared 1–5 days post-vaccination 
(n = 11), (2) girls whose symptoms appeared 5–15 days 
after the vaccination (n = 5) and (3) girls whose symptoms 
occurred 15–20 days post-vaccination (n = 2). 
Local ADRs were also reported: pain at the injection site 
(n = 5), involuntary movement at the injection arm, 
especially hand tremor (n = 1), swelling (n = 2). 
The systemic reactions observed 1–5 days after the vaccination 
consisted in low-grade fever (n = 9), headache 
(n = 12), recurrent syncope (n = 7), persistent convulsive 
hunger (n = 1), irritability (n = 3), epileptic seizures 
(n = 1), transient speech loss (n = 1), lower limbs 
paresthaesia and paresis (n = 1), hot flushes (n = 1), severe 
stomach pain (n = 4), insomnia (n = 5), hypersensitivity 
reactions (e.g. itchy skin rash, rhinitis) (n = 1), muscle pain 
(n = 5), severe gait impairment and orthostatic intolerance 
(n = 1), excessive sweating (n = 1), vomiting (n = 1). 
Clinical manifestations occurring 5–15 days after vaccination 
were asthenia (n = 8), excessive thirst (n = 3), 
severe hands and feet itching (n = 1), optic neuritis 
(n = 1). Finally, other patients complained of symptoms 
after 15–20 days after vaccination: amenorrhoea (n = 1), 
skin rashes (n = 2), tachycardia (n = 2), difficult breathing 
(n = 1), weight loss (n = 3). 
Among the most common and persistent symptoms 
(Table 4), the patients complained of memory and concentration 
impairment (n = 17), muscle pain (n = 13), 
finger and toes vascular abnormalities with skin colour and 
temperature changes (n = 13), headache (n = 12), asthenia 
(n = 9), dizziness (n = 6), abdominal pain (n = 4), 
Table 2 Patients’ and immunization features 
Patients (N) 18 
Age range 12–24 years Mean age 15.2 years 
Weight range 44–87 kg Mean weight 56.3 kg 
Height range 150–174 cm Mean height 162.3 cm 
Childhood diseases Chickenpox 
(varicella) 
MMR 
(measles, mumps 
and rubella) vaccine 
Mononucleosis Scarlet 
fever 
Poliomyelitis 
vaccine 
Fifth disease Cytomegalovirus 
(CMV) infection 
18 (patients) 8 (patients) 4 (patients) 2 (patients) 2 (patients) 1 (patient) 1 (patient) 
HPV vaccine type Gardasil" Cervarix" 
9 (patients) 9 (patients) 
Year and age patients 
that started HPV 
vaccination 
Gardasil" Cervarix" 
2008–2015 (range) 2008–2015 (range) 
11 years (mean age) 12 years (mean age) 
No. doses One dose Two doses Three doses 
4 (patients) 8 (patients) 6 (patients) 
low-grade fever (n = 3), sinus tachycardia (n = 2), skin 
rashes (n = 1). 
Discussion 
Immunization practice definitely modified the epidemiology 
of human infectious diseases since its introduction 
some centuries ago: indeed, a dramatic reduction of the 
morbidity and/or mortality in the populations recruited by 
mass vaccine campaigns was obtained [26, 27]. Despite 
these positive achievements, concerns on safety emerged 
from a number of clinical reports describing post-vaccination 
polymorphous phenomena [23, 28]. 
However, available studies reported no statistical 
association between vaccines (including those against 
HPV) and the incidence of autoimmune diseases, except 
for a few and well-defined situations [29, 30]. In the past, 
for instance, Guillain–Barre` syndrome was causally 
associated with the swine influenza vaccination campaign 
of 1976–1977. Currently, idiopathic thrombocytopenic 
purpura (ITP) has been related to vaccination against 
MMR, but the wild and natural viral infections resulted to 
have a tenfold greater risk to develop ITP, which supported 
the vaccination practice anyway. Similar observations 
have been made for other immune-mediated diseases 
following several vaccinations. Thus, the available evidence 
suggested that vaccines should not be considered a 
Table 3 Description of ADRs related to HPV immunization 
Symptoms (within 5 days post-vaccination) After first dose After second dose After third dose 
Injection site reactions 
Pain 2 2 1 
Uncontrollable and involuntary movement of the limb 1 
Swelling 1 1 
Systemic reactions 
Low-grade fever 3 5 1 
Headache 5 5 2 
Recurrent syncope 4 3 
Persistent convulsive hunger 1 
Irritability 1 2 
Epileptic seizures 1 
Temporary speech loss 1 
Lower limbs paraesthesia and paresis 1 
Hot flushes 1 
Severe stomach pain 2 1 1 
Insomnia 3 2 
Hypersensitivity reactions 1 
Leg muscle pain (myalgia) 1 3 1 
Gait and orthostatic posture impairment 1 
Excessive sweating 1 
Vomiting 1 
Symptoms (5–15 days post-vaccination) systemic reactions 
Asthenia 2 5 1 
Persistent thirst 3 
Severe hands and feet itching 1 
Optic neuritis 1 
Symptoms (15–20 days post-vaccination) systemic reactions 
Amenorrhoea 1 
Skin rashes 1 1 
Tachycardia 1 1 
Difficult breathing 1 
Weight loss 1 
risk factor leading to a greater occurrence of well-defined 
immune-mediated and neurological diseases, compared to 
the natural infections that vaccines aim at preventing 
[23, 31, 32]. 
Moreover, both the use of standardized protocols and the 
coordinated surveillance by the regulatory drug agencies 
have currently erased vaccine-related diseases due to 
malpractice (e.g. infected materials, incomplete inactivation 
of infectious agents, gross errors of administration). 
Obviously, despite the best medical practice, vaccines as 
any other drug, can display unforeseen side effects: these 
intrinsic risks are relatively rare and are considered 
acceptable in front of the health benefits produced in terms 
of life quality and expectancy. Moreover, the warnings to 
avoid vaccinations in people with allergies to some components, 
with history of previous ADRs and with transient 
(e.g. during pregnancy) or permanent (e.g. severe primary 
and secondary immunodeficiency) impairment of the 
immune system, substantially reduced the incidence of 
complications [33]. Unfortunately, unpredicted ADRs still 
occur and the individual genetic background has been 
supposed to be responsible for these phenomena, including 
autoimmune diseases and/or neurological/psychiatric syndromes, 
without a specific or identifiable pathologic alteration. 
Recently, some authors reasoned that all these 
heterogeneous post-vaccination phenomena might be the 
consequence of some immune dysfunction, putatively 
activated by the adjuvant rather than by antigenic vaccine 
fractions. Thus, they named these medical conditions as 
ASIA [34, 35]. 
The adjuvant is devoted to enhance the immune 
response to the sensitizing molecules (antigens or haptens); 
yet they may contain some pathogen-associated molecular 
patterns (PAMPs) and/or create a mild tissue injury 
exposing some damage-associated molecular patterns 
(DAMPs), which are recognized by the innate immune 
system through specific pattern recognition receptors 
(PRRs) [21, 36–38]. 
If autoimmune or immune-mediated phenomena were 
related to a vaccination, the cross-reactive adaptive 
immune response to both antigenic and adjuvant components 
of vaccine might be considered. Therefore, at the site 
of injection, at afferent lymph nodes or also at distant 
organs, autoreactive immune processes may be activated 
by the vaccine adjuvant and not only by the antigenic part 
of the vaccine. The central and peripheral nervous system 
has been supposed to be one of the targets of this 
autoimmune reaction, leading to neurological and/or psychiatric 
symptoms, diagnosed as being ASIA, in some 
(genetically) predisposed individuals [37–40]. 
Our case series included a wide spectrum of post-vaccination 
general, neurological and psychiatric symptoms 
during and/or early after the scheduled HPV immunization. 
Most patients showed an ‘‘acute phase’’ characterized by a 
variable combination of clinical manifestations, including 
low-grade fever, skin rashes, muscle pain, headache and 
sensorial disturbances. Its onset occurred at a variable time 
after HPV immunization, ranging from hours to days. 
Then, this acute phase subsided in some weeks, but the 
girls developed some chronic and/or recurrent symptoms 
resembling chronic fatigue, fibromyalgia or other functional 
somatic syndromes. The clinical pictures displayed 
by each patient were actually polymorphous, except for 
asthenia, concentration problems, sensorial impairment 
(related to temperature perception, especially), recurrent or 
persisting muscle pain, paresis and headache. Previously, 
all these girls declared excellent fitness and wellness, 
including sport practice. No significant co-morbidities or 
previous relevant diseases were reported before the HPV 
immunization. 
Currently, the diagnosis of ASIA is based upon the 
criteria proposed by Shoenfeld [39, 41], as reported in 
Table 5. It can be diagnosed whether two major criteria or 
one major and two minor criteria have been ascertained. In 
our case series, one of the major criteria is satisfied by 
definition, as all patients are joined by the exposure to HPV 
vaccine, as an external stimulus endowed of adjuvant 
properties. As summarized in Table 6, all patients presented 
at least one more of the major criteria and/or two 
minor criteria, making a diagnosis of ASIA be consistent. 
The description of our case series aimed at analysing 
clinical phenomena, being putatively immune mediated 
and arising after HPV immunization. The latency of the 
Table 4 Current and persisting ADRs in the case series 
Current symptoms Patients (n.) Duration of 
symptoms (years) 
Dizziness 6 4 
Headache 12 9 
Fever 3 4 
Skin rashes 1 1 
Asthenia 9 4 
Myalgia 13 5 
Sinus tachycardia 2 7 
Vascular skin abnormalities 13 5 
Abdominal pain 4 3 
Confusion 3 2 
Memory loss 6 3 
Concentration problems 11 4 
Depression 3 2 
Disordered sleep 8 3 
Candidiasis 1 2 
Nausea 1 3 
Paresthaesia 1 3 
onset of symptoms is quite variable, but it can be consistent 
with the occurrence of cell-mediated and/or antibody 
response against some neurological/neuromuscular 
structures. 
The majority of post-vaccination ADRs were consistent 
with severe fibromyalgia and chronic pain syndrome, 
according to the literature criteria. 
Because of these symptoms, at least 10 of these eighteen 
young girls developed a long-standing social impairment 
(school absence, sport suspension and daily activity 
impairment). 
Certainly, the diagnostic criteria for ASIA need to be 
improved and this medical category requires a better 
clinical, immunological and, possibly, genetic definition. 
Indeed, in addition to the aforementioned diagnostic 
criteria, the diagnosis is currently supported by a strict 
temporal association with the onset of symptoms and, of 
course, by the exclusion of other well-defined infectious, 
immune-mediated and oncologic diseases. ASIA is 
thought to represent an infrequent side effect of vaccinations 
due to an adjuvant or adjuvant-like stimulus 
acting on a predisposed, but not well-defined, genetic 
background [39]. Because of its rarity, its heterogeneous 
clinical expression and the frequent absence of objective 
pathological lesions and immunological signatures, 
ASIA might have escaped to pre-clinical and postmarketing 
safety studies on vaccines. Indeed, the definition 
of ASIA as post-vaccination event originated by 
a study by Zafrir and co-workers on patients affected 
with Gulf War syndrome who had received HBV 
immunization [42]. 
Among commercialized vaccines, those against HPV 
have received a lot of descriptions of medical conditions 
being consistent with the diagnosis of ASIA, regardless the 
type of vaccine. Recently, Pellegrino et al. carried out an 
interesting analysis of HPV vaccine-related ASIA epidemiology 
in the vaccine adverse event reporting system 
(VAERS), which is a large database collecting almost 30,000 
post-vaccination ADRs per year. Pooling the data until the 
end of 2013, the authors reported more than 26,000 ADRs 
after HPV vaccine: of these, about 8 %have been labelled as 
being probable or possible ASIA, according to the Shoenfeld 
and Agmon-Levin’s guideline for the diagnosis. A strong 
causality evaluation between HPV vaccination and ASIA 
has been supposed in this study [43]. Unfortunately, most 
descriptions of HPV post-vaccination phenomena consistent 
with ASIA have been single cases and small case series, 
where only the temporal link was evident. 
A recent observational analysis promoted by UK 
Medicines and Healthcare products Regulatory Agency 
(MHRA) investigated the association between bivalent 
HPV vaccine and chronic fatigue syndrome (CFS) that is 
considered one of the main expressions or evolution of 
ASIA. No increase of CFS incidence was noticed in girls 
aged 12–20 years old after the introduction of such an 
immunization [44]. 
Moreover, in 2015, the European Medicine Agency 
(EMA) revised the safety profile of HPV vaccines as 
Table 5 Proposed diagnostic criteria of autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 
Major criteria 
Previous exposure to an external stimulus (i.e. vaccine, adjuvant, silicone, nucleic acids, fragments of bacterial cell 
walls) 
One of the following ‘‘typical’’ manifestations 
Myalgia/myositis, muscle weakness 
Arthralgia and/or arthritis 
Chronic fatigue, non-refreshing sleep or sleep disturbances 
Neurological manifestations (especially if associated with demyelination) 
Memory loss and cognitive impairment 
Fever 
Dry mouth 
Improvement of symptoms after the removal of the triggering agent 
Typical biopsy of the involved organs 
Minor criteria 
Appearance of autoantibodies or autoantibodies directed against the suspected adjuvant 
Other clinical manifestations (i.e. functional somatic syndromes) 
Association with specific HLA haplotypes (i.e. HLA-DRB1, HLA-DQB1) 
Development of autoimmune diseases 
Diagnostic requirements: 
Two major criteria 
One major criteria ? two minor criteria 
regards the occurrence of complex regional pain syndrome 
(CRPS) and postural orthostatic tachycardia syndrome 
(POTS). Such a revision was carried out through 
the Pharmacovigilance Risk Assessment Committee 
(PRAC) and the Global Advisory Committee on Vaccine 
Safety (GACVS), which were not able to find enough 
scientific evidence so far to support a clear causal link 
between HPV vaccine and the aforementioned syndromes 
Table 6 ASIA diagnostic criteria in our case series 
Patients Major 
criteria 
(1st) 
Major criteria (2nd) Minor criteria (1st) Minor criteria (2nd) 
# 1 Cervarix" Typical symptoms 
(CFS, myalgia, arthralgia) 
Autoantibodies 
(ANA, anti-cardiolipin 
IgM) 
Other clinical manifestations (fibromyalgia) 
# 2 Cervarix" Typical symptoms 
(low-grade fever, memory loss, CFS) 
– – 
# 3 Gardasil" Typical symptoms 
(muscle weakness, arthralgia, CFS) 
– Other clinical manifestations (neuropathy) 
# 4 Gardasil" Typical symptoms 
(muscle weakness, dry mouth, sleep 
disturbances, CFS) 
– 
# 5 Gardasil" Typical symptoms (low-grade fever, skin 
rashes, cognitive impairment) 
HLA haplotype 
(HLA-DRB1) 
Other clinical manifestations (fibromyalgia) 
# 6 Cervarix" Typical symptoms (muscle weakness, skin 
rashes, sleep disturbances, memory loss, 
CFS) 
– Development of autoimmune disease 
(diabetes mellitus type 1) 
# 7 Gardasil" Typical symptoms (muscle weakness, 
recurrent syncope, pins and needles) 
– – 
# 8 Gardasil" Typical symptoms (muscle weakness, dry 
mouth 
Autoantibodies (antithyroglobulin 
and anti- 
TPO) 
Development of autoimmune disease 
(diabetes mellitus type 1) 
# 9 Gardasil" Typical symptoms (muscle weakness, skin 
rashes, cognitive impairment, CFS) 
– Other clinical manifestations (fibromyalgia) 
# 10 Cervarix" Typical symptoms 
(muscle weakness, CFS) 
– Development of autoimmune diseases 
(Optic neuritis) 
#11 Cervarix" Typical symptoms (arthralgia, cognitive 
impairment, muscle weakness) 
– Other clinical manifestations (fibromyalgia) 
# 12 Cervarix" Typical symptoms 
(arthralgia, muscle weakness, dizziness, 
recurrent syncope, asthenia) 
– – 
# 13 Gardasil" Typical symptoms 
(nausea, asthenia, insomnia, syncope) 
– Other clinical manifestations (fibromyalgia, 
Raynoud syndrome) 
# 14 Gardasil" Typical symptoms (arthralgia, sleep 
disturbances) 
Autoantibodies 
(anti-TG and anti-TPO) 
Development of autoimmune disease 
(autoimmune thyroiditis) 
# 15 Cervarix" Typical symptoms (arthralgia, skin rashes) – Development of autoimmune disease 
(Schonlein–Henoch purpura and IgA 
nephropathy) 
# 16 Gardasil" Typical symptoms (fever, myalgia, myositis, 
cognitive impairment) 
– Other clinical manifestations (fibromyalgia) 
# 17 Cervarix" Typical symptoms (fever, CFS, sleep 
disturbances) 
– Other clinical manifestations 
(irritable bowel disease, fibromyalgia) 
# 18 Cervarix" Typical symptoms (arthralgia, myalgia, 
CFS) 
Autoantibodies 
(anti-cardiolipin IgM and 
IgG, anti-2GPI IgM and 
IgG) 
Other clinical manifestations (pseudoneurological 
somatoform disorder) 
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and, thus, to alter the current recommendations for HPV 
immunization programme [45]. 
These studies were prompted by the burden of reports 
regarding syncope, asthenia and pain syndromes occurring 
after HPV immunization [46, 47]. Recently, Martinez- 
Lavin published an interesting clinical report where two 
girls have developed severe incapacitating fibromyalgialike 
illness, after one and two doses of HPV inoculation, 
respectively [48]. 
This same author speculated that post-vaccination 
fibromyalgia, POTS and CRPS might be due to a dysautonomia, 
precisely a sympathetic nervous system dysfunction, 
because of a small fibre neuropathy triggered by 
the HPV immunization in susceptible people. Actually, 
such a hypothesis has been endorsed by Kinoshita et al. 
[49], who described a case series of 44 girls (aged 
11–17 years) complaining of several symptoms after HPV 
immunization. Interestingly, in addition to headache, general 
fatigue, limb pain and coldness, most patients showed 
signs of vascular instability at the extremities, including a 
slight to moderate decrease of toes and fingers temperature, 
as many patients of our case series did. 
The aforementioned EMA investigation had been 
prompted mainly by a retrospective analysis (carried out in 
Denmark) on 53 patients developing orthostatic intolerance 
and other symptoms consistent with autonomic dysfunction 
within two months after the quadrivalent HPV vaccination 
[50]. The authors stated a recognizable pattern of 
somatoform symptoms (headache, localized or diffuse 
neuropathic pain, dysautonomic disturbances, excessive 
fatigue and cognitive dysfunctions), where different clinical 
entities, namely POTS, CRPS, fibromyalgia and CFS, 
could be included. ASIA might be the diagnostic category 
including all these syndromes, but the inclusion criteria 
should be substantiated through further studies providing 
new insights into its neuropathic pathophysiology and 
adjuvant-triggered/immune-mediated pathogenesis. In this 
perspective, the first and mandatory step could be focusing 
the epidemiology of these post-vaccination phenomena and 
selecting/collecting an appropriate study population of girls 
complaining of this pattern of symptoms. Martinez-Lavin 
et al. recently published the results of questionnaires proposed 
to 45 patients developing chronic disturbances 
within 3 months after HPV vaccination, by means of three 
validated self-applied questionnaires evaluating the different 
groups of symptoms described after HPV immunization 
or, more in general, in ASIA patients: (1) the 2010 
ACR Fibromyalgia Diagnostic Criteria Survey; (2) the 
COMPASS-31 test, exploring the autonomic dysfunction; 
(3) the S-LANSS questionnaire, evaluating the neuropathic 
component in pain syndromes [51]. We suggest drawing a 
specific questionnaire summarizing all these clinical 
aspects, to be administered to all the subjects receiving 
HPV vaccination in a perspective observational study. 
Such an approach could provide certain data on the real 
incidence of ASIA after HPV immunization, definitely 
ruling out the potential bias deriving from pre-existing 
subjective complaints. Then, a standardized and international 
consensus protocol of investigation ought to be 
planned on these identified cohorts of patients, in order to 
clarify the existence and the mechanisms of this puzzling 
syndrome. 
Although no cause/effect evidence between HPV 
immunization and non-organic symptoms has been detected 
so far, the strong burden of concerns expressed by the 
parents’ associations from several European countries 
should not be underscored at all. 
A database of 35 young girls immunized against HPV 
through Gardasil" between 2008 and 2013 in France, who 
showed similar symptoms as our case series (and who 
received also a final diagnosis of autoimmune disease in 
some cases), was published by an independent parents’ 
association [52]. 
In Spain, the Asociacion de Afectadas pro la Vacuna del 
Papiloma (AAVP) collected 42 cases from 2008 to 2014: in 
addition to few cases of demyelinating/autoimmune diseases, 
most patients developed somatoform/functional 
disorders or not well-defined patterns of symptoms without 
a final diagnosis [53]. 
Again, in the UK, another parents’ association, named 
Association of HPV Vaccine Injured Daughters (AHVID), 
currently counts 265 members: through a questionnaire 
which has been responded to by almost 100 families so far, 
variable patterns of neuropathic disorders, being labelled as 
POTS, CRPS, CFS or fibromyalgia, were reported in most 
cases [54]. 
All these alerting reports are not institutional and cannot 
be reputed as systematic epidemiologic investigations; 
however, in our opinion, they have to be taken into adequate 
account to reach definite conclusions upon the relationship 
between HPV vaccines and ASIA/functional 
somatoform diseases, through further studies. This will be 
the only way to clarify the real risk of HPV vaccines, as 
regards these specific health issues: that will help to retract 
all potential and/or unfounded concerns related to HPV 
immunization, and, thus, will reinforce the perception of 
safety and effectiveness of HPV vaccines among people all 
over the world. Conversely, the identification of a genetically 
and/or immunologically cohort of young girls being 
potentially exposed to these kinds of diseases might lead to 
the selective exclusion from this immunization practice. 
Indeed, like the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) and other European Pharmacovigilance, 
other systems have been notified about this 
kind of side effects regarding HPV vaccines. For instance, 
the Netherland Pharmacovigilance Centre Lareb received 
1271 reports of Adverse Events Following Immunization 
(AEFI) with Cervarix" since the introduction of the 
National Immunization Programme in 2009, according to 
the data analysis updated at December 2015: 231 reports 
were about long-lasting AEFI, whose duration was 
2 months or more, and most related complaints were persistent/ 
recurrent fatigue, headache, dizziness, musculoskeletal 
discomfort and syncope [55]. Interestingly, after 
consulting the available medical records and the healthcare 
practitioners dealing with these patients, no medical 
explanation for all these long-lasting AEFI was found. 
According to this analysis, a causal relation between Cervarix 
" and the reported long-lasting AEFI could not be 
concluded, but neither excluded, based upon the available 
data. Previously, in 2013, the same institution edited an 
overview of the reports on long-lasting fatigue following 
immunization with Cervarix". As many others, the authors 
observed that the age of vaccinated girls had to be taken 
into account as potential confounding factor, but they 
concluded that additional epidemiological research was 
needed anyway, in order to confirm or reject a causal link 
[56]. It is well known that severe and/or long-lasting fatigue, 
like other somatoform symptoms, are not uncommon 
in young females, but this issue could be ascertained 
through an appropriate epidemiological and observational 
investigation. The girls affected by these symptoms after 
HPV immunization in our case series, as well as in databases 
reported by parents’ associations, had been completely 
healthy and had never complained of fatigue or 
somatoform symptoms before the administration of one or 
more doses of the HPV vaccine. 
A plan of prospective and specific epidemiological 
studies, among active surveillance of post-vaccination 
ADRs, addressed to face the HPV immunization major 
concerns, was attempted in Italy through the National 
Centre of Epidemiology, Surveillance and Health Promotion. 
The second report on post-marketing surveillance of 
vaccines in Italy described the side effects in a cohort of 
12,990 female subject aged 9–16 years who received free 
immunization through the Local Health System Institutions 
in the period going from June 2009 to December 2011. The 
main complaints observed were local reactions and symptoms 
like headache, muscles and joint pains. However, this 
surveillance was limited to symptoms arising within 
15 days after the vaccination. Moreover, this analysis 
included only girls who voluntarily accepted to participate 
to the study, moreover, it was not possible to ascertain the 
effective surveillance coverage in each recruited vaccination 
centre [57]. It might be reasonable comparing girls 
receiving and refusing freely available HPV vaccination, 
planning a longer follow-up period and collecting data by 
telephone interviews taking advantage of specific questionnaires 
for self-reported symptoms. This approach will 
assess the actual burden of long-lasting AEFI and might 
identify a specific population to be investigated in order to 
detect genetic traits and/or prognostic biological markers, 
predicting an increased risk for long-lasting AEFI. Currently, 
few studies describing a positive correlation 
between post-vaccination phenomena and genetic variants, 
such HLA haplotypes or single nucleotide polymorphisms, 
are currently available and have been mainly addressed to 
transient symptoms, such as fever, arthralgia and other 
systemic ADRs [19, 58]. Recently, an increased risk of 
narcolepsy, which could be included in the spectrum of 
ASIA, was described after AS03-adjuvanted H1N1 vaccination 
and, importantly, the authors proposed an association 
with HLA-DQB1*06:02 [59, 60]. Thus, the possibility 
to find similar genetic or biological markers might increase 
the safety of immunization programs and decrease the 
existence of vaccine refusal movements. 
Conclusively, our study highlighted some important 
post-vaccination phenomena temporally linked to HPV 
immunization, which needs further epidemiological analysis 
and biological investigations in order to establish or 
exclude a causal relation. 
The exact incidence of these post-vaccination syndromes 
in the general population has not been known yet and a 
definite cause/effect link between HPV vaccine-related 
immune activation and symptoms onset has to be established. 
However, the studies on fibromyalgia, chronic pain 
with dysautonomia and CFS considered that a previous 
subclinical and spontaneous reaction to viral agents could be 
often involved in the start of pain and functional impairment. 
Therefore, a link between HPV vaccination and some neuromuscular 
and systemic impairment might be possible, 
considering also the immunization properties displayed by 
HPV vaccines, according to several studies [61]. 
Moreover, the HPV vaccine formula, containing also 
high polysorbate 80 (50 mcg) concentration, might also 
induce a greater meningeal permeability leading to a 
facilitated entrance of many substances to the central nervous 
system. Based upon these observations, it might be 
speculated that this vaccine—and not others—could induce 
some abnormal activation of immune competent cells in 
the central nervous system, such as the glia [62, 63]. 
Finally, we believe that our commitment should be planning 
epidemiological and genetic investigations in order to 
clarify the existence and pathophysiology of HPV-related 
syndromes. Hopefully, this approach might lead to a screen 
test for this risk and, eventually, to prevent it: indeed, these 
syndromes are currently an orphan drug area, as all the 
experimented therapies have not shown any significant 
beneficial effect. Last but not least, a proper treatment for 
these somatoform syndromes is urgently needed, as the 
current painkilling drugs, including opiates, resulted to be 
ineffective, or paradoxically, pain enhancers. 
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